NPM1 and acute myeloid leukemia: Consequently, patients with NPM1mut CMML should be considered for a more intensive, AML-like treatment based on chemotherapy ± allo-HSCT when possible.5,8,11-18 Moreover, NPM1 mutations are an ideal target for the assessment of measurable residual disease (MRD) by RT-PCR.